arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

LIFECORE BIOMEDICAL, INC. \DE\

LFCR
$5.02 ▲ +0.18 (+3.72%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
17 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

LIFECORE BIOMEDICAL, INC. \DE\ faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $174.8M
Dividend Yield
Revenue Growth 0.5%
Op. Margin -13.4%
ROIC -13.1%
FCF / Share $-0.39
Trailing P/E
Price / Book 139.1x
FCF Yield
Debt / Equity 97.63
info Valuation on last close. End-of-day price, Aug 7, 2026.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$128.87M
— +0.5%
Net Income Profit after all expenses
$-38.72M
↓ -422.3%
Operating Margin Operating profit as % of sales
-13.4%
↓ -94.1% 13th
FCF / Share Free cash flow per share
$-0.39
↑ +34.3%
Long-Term Debt Long-term obligations
$130.44M
↑ +4.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
11
Financial Health
23
Cash Quality
34

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 65 quarters